TY - JOUR
T1 - Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report
T2 - GOLD executive summary
AU - Vogelmeier, Claus F.
AU - Criner, Gerard J.
AU - Martinez, Fernando J.
AU - Anzueto, Antonio
AU - Barnes, Peter J.
AU - Bourbeau, Jean
AU - Celli, Bartolome R.
AU - Chen, Rongchang
AU - Decramer, Marc
AU - Fabbri, Leonardo M.
AU - Frith, Peter
AU - Halpin, David M.G.
AU - López Varela, M. Victorina
AU - Nishimura, Masaharu
AU - Roche, Nicolas
AU - Rodriguez-Roisin, Roberto
AU - Sin, Don D.
AU - Singh, Dave
AU - Stockley, Robert
AU - Vestbo, Jørgen
AU - Wedzicha, Jadwiga A.
AU - Agusti, Alvar
N1 - Publisher Copyright:
Copyright © 2017 the American Thoracic Society. Published with permission from the American Thoracic Society. Design and branding are copyright © ERS 2017.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.
AB - This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.
UR - http://www.scopus.com/inward/record.url?scp=85019014236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019014236&partnerID=8YFLogxK
U2 - 10.1183/13993003.00214-2017
DO - 10.1183/13993003.00214-2017
M3 - Article
C2 - 28182564
AN - SCOPUS:85019014236
SN - 0903-1936
VL - 49
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 3
M1 - 1700214
ER -